Earnings summaries and quarterly performance for MESA LABORATORIES INC /CO/.
Executive leadership at MESA LABORATORIES INC /CO/.
Board of directors at MESA LABORATORIES INC /CO/.
Research analysts covering MESA LABORATORIES INC /CO/.
Recent press releases and 8-K filings for MLAB.
McFarlane Lake Mining Reports Strong Drill Results and Expands Drilling Program
MLAB
New Projects/Investments
- McFarlane Lake Mining Limited announced that drill hole JU8-26-142 at its Juby Gold Project intersected 6.58 g/t gold over 10.35 metres, contained within a broader intersection of 3.32 g/t gold over 22.35 metres.
- These positive results have led the company to increase its drilling program in the '826' zone by an additional 400 metres, bringing the total additional drilling in this zone to 1,000 metres.
- The Juby Gold Project has a current (effective September 29, 2025) Indicated Mineral Resource Estimate of 1.01 million ounces of gold at 0.98 g/t gold and an Inferred Mineral Resource Estimate of 3.17 million ounces of gold at 0.89 g/t gold.
3 days ago
Mesa Labs Announces Third Quarter Results
MLAB
Earnings
Revenue Acceleration/Inflection
- Mesa Laboratories, Inc. (MLAB) reported total revenues of $65,126 thousand for the third fiscal quarter ended December 31, 2025, marking a 3.6% increase compared to the same period last year.
- The company demonstrated strong profitability, with operating income increasing 38.0% to $7,975 thousand and net income rising 317.0% to $3,630 thousand, or $0.65 per diluted share. Non-GAAP adjusted operating income (AOI) excluding unusual items increased 15.4% to $17,072 thousand, achieving 26.2% as a percentage of revenues.
- Mesa Labs repaid $8.7 million of debt, successfully reducing its Total Net Leverage Ratio to 2.62 as of December 31, 2025.
- Key divisional performance included 17.5% organic revenue growth in Biopharmaceutical Development and 6.0% in Sterilization and Disinfection Control, while Clinical Genomics experienced a 7.1% organic decline primarily due to a 57% contraction in China revenues.
4 days ago
Mesa Laboratories Announces Third Fiscal Quarter 2026 Results
MLAB
Earnings
Debt Issuance
Revenue Acceleration/Inflection
- Mesa Laboratories reported total revenues of $65,126 thousand for the third fiscal quarter ended December 31, 2025, marking a 3.6% increase compared to the prior year.
- Operating income significantly increased by 38.0% to $7,975 thousand, and net income grew 317.0% to $3,630 thousand, or $0.65 per diluted share.
- The company's non-GAAP adjusted operating income (AOI) excluding unusual items increased 15.4% and represented 26.2% of revenues.
- Mesa Laboratories repaid $8.7 million of debt, bringing its Total Net Leverage Ratio down to 2.62 as of December 31, 2025.
4 days ago
McFarlane Lake Mining Announces Early Gold Exploration Success
MLAB
New Projects/Investments
- McFarlane Lake Mining Limited announced early success in its exploration campaign at the Juby Gold Project, extending the "826 Zone" gold mineralization by 80 metres.
- New drilling in the "826 Zone" included drill hole JU826-141, which intersected near-surface gold mineralization of 2.09 g/t Au over 4.17 m within a broader interval of 0.70 g/t Au over 28.17 m.
- Assaying of previously unsampled drill core from 2003 to 2011 also yielded significant results, including 7.2 g/t Au over 1.2 m from drill hole JU-03-36.
- The Company has approved an additional 500 to 600 metres of drilling to further define the 826 Zone.
- The Juby Gold Project has a current (effective September 29, 2025) NI 43-101 compliant Mineral Resource Estimate of 1.01 million ounces of gold in the Indicated category and 3.17 million ounces of gold in the Inferred category.
Jan 22, 2026, 12:35 PM
Northisle Provides Corporate and Exploration Update and 2026 Execution Plan
MLAB
New Projects/Investments
Management Change
Board Change
- Northisle completed 20,297 meters of exploration and infill drilling across 58 holes at the North Island Project in 2025, which included identifying copper-gold mineralization at the Cougar target and extending mineralization at West Goodspeed.
- The company is advancing the North Island Project towards a Pre-Feasibility Study (PFS), with completion targeted for Q4 2026.
- Key milestones for 2026 include assay results from infill drilling at Northwest Expo (Q1), initial metallurgical test results for the PFS (Q2), an integrated resource update (Q2), and the announcement of North Island PFS results (Q4).
- Northisle expanded its team with the addition of Alex Davidson and Jill Donaldson to the Board of Directors, and the appointments of Kevin O’Kane as Chief Operating Officer, Dr. Pablo Mejia Herrera as VP Exploration, and Brian Ferrey as VP Corporate Development & Investor Relations.
Jan 21, 2026, 11:57 AM
Mesa Labs Discusses Financial Performance, Debt Reduction, and Growth Outlook at J.P. Morgan Healthcare Conference
MLAB
Revenue Acceleration/Inflection
Debt Issuance
M&A
- Mesa Labs (MLAB) is a diversified tools company focusing on mission-critical quality controls for regulated biopharmaceutical markets, with over 75% recurring revenue from consumables and services.
- The company reported approximately $240 million in revenue last year (implied FY 2025) with a 63% gross margin and a five-year CAGR of 15%.
- Mesa Labs has reduced its debt leverage from 3.8-3.9 times after the GKE acquisition to slightly under 3 times as of September 30th, with a goal to reach below 2.5 times over the next 12 months.
- Management anticipates an acceleration in core organic growth from the current 3.5%-4% to a mid-single-digit plus range, potentially high single digits, as clinical trial starts recover and market headwinds subside.
Jan 15, 2026, 12:30 AM
Mesa Labs Discusses Financial Performance, Growth Strategy, and Debt Reduction at J.P. Morgan Healthcare Conference
MLAB
Revenue Acceleration/Inflection
Debt Issuance
M&A
- Mesa Labs reported approximately $240 million in revenue last year, with a five-year CAGR of around 15% and a gross margin close to 63%.
- The company's core organic growth rate has increased to around 3.5% to 4% over the last few years, with 75% plus recurring revenue.
- Debt leverage, which was approximately 3.8-3.9 times after the GKE acquisition, has been reduced to below 3 times as of September 30th, with a target to go below 2.5 times in the next 12 months.
- Management expects accelerated growth as clinical trial starts recover, aiming for a mid-single-digit plus range, and notes that current valuations are 50%-60% of other profitable diversified life science tools companies due to small-cap compression.
Jan 15, 2026, 12:30 AM
Mesa Laboratories Reports FY25 Financials and Q1/Q2 FY26 Performance
MLAB
Earnings
Revenue Acceleration/Inflection
Demand Weakening
- Mesa Laboratories, Inc. (MLAB) reported FY25 revenues of $240,978 thousand, an 11.5% year-over-year increase, with a gross profit margin of 62.6% and adjusted operating income (AOI) excluding unusual items of 23.5% of revenues. The company recorded a net loss of $(1,974) thousand for FY25.
- For the first two quarters of fiscal year 2026, MLAB's revenues were $59,543 thousand in 1Q26 and $60,737 thousand in 2Q26, with net income of $4,742 thousand and $2,476 thousand, respectively.
- MLAB has demonstrated long-term financial growth, achieving a 13% revenue CAGR and 9% AOI CAGR from 2015-2025. The company is strategically focused on high-growth verticals, increasing its exposure to Biopharmaceutical, Medical Device, and Genomics from 50% to 69% over the last five years.
- Key divisional FY25 revenues include Sterilization & Disinfection Control at $93.4M and Biopharmaceutical Development at $48.7M, which is benefiting from strong demand for GLP-1s. Conversely, Clinical Genomics, with $47.1M in FY25 revenues, continues to experience contraction in China.
Jan 15, 2026, 12:30 AM
Mesa Laboratories Discusses Financial Performance, Growth Outlook, and Valuation at J.P. Morgan Healthcare Conference
MLAB
Revenue Acceleration/Inflection
Guidance Update
New Projects/Investments
- Mesa Laboratories reported approximately $240 million in revenue last year, with a five-year compound annual growth rate (CAGR) of around 15%.
- The company maintains high profitability with a gross margin close to 63% and generates over 75% of its revenue from recurring sources like consumables and services.
- Mesa Labs expects its core organic growth rate, which has been 3.5% to 4% recently, to accelerate to a mid-single-digit plus range, potentially reaching high single digits in a good year, driven by a recovery in clinical trial starts and growth across its segments including Calibration Solutions, Clinical Genomics, Steroline disinfection control, and Protein Analytics.
- Management noted that the company's valuation is currently at 50%-60% of other profitable diversified life science tools companies, anticipating a closing of this multiple gap as market conditions stabilize.
Jan 15, 2026, 12:30 AM
MLAB Provides Business Updates and Outlook at Jefferies Conference
MLAB
Revenue Acceleration/Inflection
New Projects/Investments
Demand Weakening
- Biopharmaceutical development achieved 17% growth in the quarter, while clinical genomics saw double-digit growth in North America and Europe, significantly offset by a 60% decline in China.
- The company implemented $3 million in cost reductions primarily within its clinical genomics business, while simultaneously reinvesting in sterility testing (SDC) for commercialization.
- Debt leverage has been reduced to 3 times, down from 3.8-3.9 turns, with a strategic goal to further decrease it to 2.5 times.
- Management anticipates sequential revenue improvement in Q3 and expects the second half of the year to be incrementally better than the first half, partly due to resolving production challenges in sterility testing.
Nov 20, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more